Unlocking the true value

of hits derived from HTS   


Webinar Summary:

Drug discovery research is a complex endeavor that involves multiple stages. By providing the initial set of compounds with the potential to be developed, the hit identification phase, lays the groundwork for the next phases and significantly influences the success of the entire drug development process.

High-Throughput Screening (HTS) revolutionized drug discovery and was shown to be one of the most powerful tools for hit identification. However, an HTS campaign “per se” is typically not sufficient to support the selection and prioritization of the chemical matter identified. Therefore, focused follow-up activities become crucial for choosing the most promising hits.

In this webinar, we will focus on our “HIT QUALIFICATION” strategy as an effective and fundamental tool to unlock the true value of hits derived from HTS campaigns run in Axxam. We will talk about how biology and chemistry expertise can melt together to ensure a comprehensive validation, optimization, and prioritization of the best-suited molecules, thus enhancing the probability of downstream success and maximizing the value of this early yet impactful phase of drug discovery research.  


Drug discovery; Hit identification; High-Throughput Screening (HTS); Integrated research; Hit qualification; Hit selection; Medicinal chemistry.


  • Angela Molteni, Head of HTS automation , Axxam

  • Iolanda Micco, Head of Discovery chemistry, Axxam

Angela Molteni is currently the Head of the High-Throughput Screening and Automation group at Axxam, coordinating a team of 11 people and 4 fully automated robotic systems. She has a Master’s degree in Molecular Biology, and before joining Axxam in 2001, she gained experience in biochemistry and in the development of biochemical assays for high-throughput screening (HTS9 in pharmaceutical companies.

Her deep expertise in the HTS field, have been consolidated over the last 16 years, executing HTS campaigns on biochemical and cellular assays with a wide variety of read-outs, acting as the automation manager in programming and upgrading the robotic systems, and performing data analysis of screening campaigns or compound profiling activities.

Dr. Iolanda Micco currently serves as the Head of Discovery Chemistry at Axxam. Holding a Ph.D. in medicinal chemistry from the University of Siena, Italy, she brings over 15 years of international experience in pivotal management and strategic roles.

Her commitment to advancing pharmaceutical science started at Siena Biotech, in Italy, where she led interdisciplinary programs, focused on the hit identification of small molecules with potential applications in neurodegenerative diseases. She later shared her expertise and dedication by teaching chemistry and medicinal chemistry at a college in Singapore.

After her journey in the Asian community, she moved to Denmark where she contributed significantly to the field of DNA-encoded libraries as Associate Director of Chemistry and Alliances at Vipergen. Finally, prior to her current role, Iolanda served as the Director of Medicinal Chemistry at Scandion Oncology in Denmark, leading preclinical activities in the field of drug resistance.

Iolanda’s journey showcases her dedication to pushing the boundaries of drug discovery, blending and offering a medicinal chemistry eye through the lens of a diversified knowhow.

Scroll to Top